ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Anti-ErbB2 / HER2 Antibody [4D5-8] (A279369)

This product is discontinued

Anti-ErbB2 / HER2 Antibody [4D5-8] (A279369) has been discontinued and is no longer available.

View all available products.

Name
Anti-ErbB2 / HER2 Antibody [4D5-8]
Description
Human monoclonal [4D5-8] antibody to ErbB2 / HER2.
Applications
ELISA
Reactivity
Human
Immunogen
A431 cells (human epidermoid carcinoma), overexpressing EGFR.
Host
Human
Clonality
Monoclonal
Clone ID
4D5-8
Isotype
IgG1
Conjugate

Unconjugated

Purification
Protein A affinity chromatography.
Concentration
1 mg/ml
Purity
>98% (by SDS-PAGE).
Product Form
Liquid
Formulation
Supplied in Phosphate Buffered Saline with 0.02% ProClin 300.
Storage
Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.
General Notes
Human Anti-ErbB2 antibody, clone 4D5-8 is a research grade biosimilar of the monoclonal antibody drug trastuzumab. This product is supplied in a research grade format, i.e. in PBS buffer with preservative, it is not manufactured or formulated in the same way as the therapeutic reference product. A preservative free version is available on request. This product is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic trastuzumab antibody clone 4D5-8.Human Anti-ErbB2 antibody, clone 4D5-8 is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-trastuzumab antibodies, for example HCA168 and HCA167. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-trastuzumab antibody in IgG1 format as a reference standard, for example HCA176 or HCA177.Trastuzumab, also known as Herceptin, is a drug used in the treatment of HER2 positive breast cancer and other HER2 over-expressing cancers including HER2-positive metastatic cancers of the gastrointestinal tract. Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.This product is NOT FOR THERAPEUTIC USE.View a summary of supporting anti-trastuzumab antibody products.
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.